Vaccine

Eli Lilly to Pursue mRNA Cancer Vaccines with CureVac Pact

11 monthes ago   |   By Xconomy

Eli Lilly is getting a foothold in messenger RNA cancer vaccines through a deal with CureVac that could develop up to five new therapies. Indianapolis-based Lilly will pay CureVac, headquarted in Germany, $50 million up front, plus make an equity investment in the company valued at nearly $53 million, according to the agreement announced Wednesday. The deal calls for CureVac to use its proprietary technology to design, formulate, and manufacture the vaccine candidates. Lilly will handle clinical testing, and if approved, oversee commercialization of the drugs. If all five vaccines reach...
Read more ...

 

Lilly, CureVac pen $1.8B mRNA cancer vaccine deal

Lilly, CureVac pen $1.8B mRNA cancer vaccine deal

11 monthes ago   |   By Fierce Biotech

Eli Lilly is putting up $1.8 billion to work with CureVac on five mRNA cancer vaccines. The back-loaded deal moves Lilly into an emerging field that seeks to use mRNA to guide immune attacks on tumors.
Read more ...

 


Search by Tags

   Vaccine      Vaccines      Therapies      Drugs      Drug      Cancer      Manufacturing      Clinical      RNA      Boston blog main      Indiana      Indiana blog main      Indiana top stories      National blog main      Abemaciclib      Bill & Melinda Gates Foundation      BioNtech      Biotech      Boehringer Ingelheim      Cancer      Cancer vaccines      Clinical trials      CureVac      Eli Lilly      FDA      Food and Drug Administration      International AIDS Vaccine Initiative      Life Sciences      ModeRNA Therapeutics      MRNA      RaNA Therapeutics      Sanofi      Immunity  


14th International Conference on Generic Drugs and Biosimilars

Conference series takes pleasure in inviting the scientific community across the globe to attend the 14th International Conference on Generic Drugs & Biosimilars during... Read more ...

14th International Conference on Generic Drugs and Biosimilars

14th International Conference on Generic Drugs and Biosimilars November 15-16, 2018 | Berlin, Germany Best Western Premier Airporthotel Fontane Berlin Theme: A new Era in... Read more ...

Annual DIA Meeting 2017

Annual DIA Meeting 2017

From June 18-22, CORE Clinical will be attending the DIA conference in Chicago. From the people who pioneered the imaging CRO comes new thinking in image management, workflow... Read more ...

UN Proposals to Weaken IP Will Not Benefit Patients

UN Proposals to Weaken IP Will Not Benefit Patients

Next week the 73rd session of the United Nations General Assembly will convene in New York City. Among the many high-level meetings taking place, the UN will be evaluating... Read more ...

Amarin Soars as Fish Oil Pill Cuts Risk of Strokes in Long-Awaited Study

Amarin Soars as Fish Oil Pill Cuts Risk of Strokes in Long-Awaited Study

Can fish oil help prevent, or reduce the risk of heart disease? Several studies have failed to show that it can. But Amarin this morning is releasing data from a massive study... Read more ...

Adobe-Marketo Deal Could Spur Marketing Tech Tie-Ups, New Strategies

Adobe-Marketo Deal Could Spur Marketing Tech Tie-Ups, New Strategies

Marketo almost didn't get off the ground. It was 2006, and Jon Miller and his Marketo co-founders were struggling to raise money from investors for their marketing technology... Read more ...

Topping the Charts

San Diego Magazine “Physicians of Exceptional Excellence” survey, an annual opportunity for doctors across the region to vote for much-admired colleagues. ]]> ... Read more ...

Mosquitoes that can carry malaria eliminated in lab experiments

Researchers have eliminated caged mosquitoes using 'gene drive' technology to spread a genetic modification that blocks female reproduction. Read more ...

Burst of morning gene activity tells plants when to flower

Researchers have discovered that the gene FT - the primary driver of the transition to flowering in plants each spring - does something unexpected in Arabidopsis thaliana... Read more ...

DNA islands effective as 'anti-bacterial drones'

Genomic 'islands' that evolved from viruses can be converted into 'drones' that disable Staphylococcus aureus, bacteria that are often resistant to antibiotics, a new study finds. Read more ...

AnaptysBio's lead IL-33 antibody clears midstage test in asthma

Next-generation antibody company AnaptysBio has positive data for its lead pipeline drug etokimab in a third indication, adding asthma to its earlier wins in peanut allergy and... Read more ...

Nightstar posts early-phase data on retinal gene therapy

Nightstar Therapeutics has presented early clinical data on its gene therapy treatment for X-linked retinitis pigmentosa. Around half of the patients in higher-doses cohorts... Read more ...

Former Merck clinical research VP Arthur Santora joins Entera Bio as CMO

Former Merck clinical research leader Arthur Santora, M.D., Ph.D., is coming out of retirement to serve as the new chief medical officer of Entera Bio, to help the company... Read more ...